~(18)F标记乏氧组织显像剂的研究进展

doi:10.7538/tws.2004.17.04.0241

同位素 ›› 2004, Vol. 17 ›› Issue (4 ): 241-241 .DOI: 10.7538/tws.2004.17.04.0241

~(18)F标记乏氧组织显像剂的研究进展

作者

@汪建军$放射性药物教育部重点实验室,北京师范大学化学系!北京 100875 @张剑英$放射性药物教育部重点实验室,北京师范大学化学系!北京 100875 @朱霖$放射性药物教育部重点实验室,北京师范大学化学系!北京 100875

收稿日期:2003-09-23 出版日期:2004-11-20 发布日期:2004-11-20

The Development ~(18)F Labeled Hypoxic Imaging Agents

WANG Jian-jun, ZHANG Jian-ying, ZHU Lin(Key Laboratory of Radiopharmaceuticals (Beijing Normal University) , Ministry of Education , Department of Chemistry, Beijing Normal University, Beijing 100875, China)

Received:2003-09-23 Online:2004-11-20 Published:2004-11-20

摘要/Abstract

摘要： 乏氧组织显像剂是当前放射性药物研究的热点之一。随着PET显像技术的迅速发展,18F标记的放射性药物在临床上的应用越来越广泛。18FMISO(18F-氟米索硝唑)是现今核医学领域研究最多的18F标记的乏氧组织显像剂,它自身存在一些缺点,而新的乏氧组织显像剂仍在进一步的研究中。

关键词: 18F, 乏氧组织显像剂, 肿瘤, 标记

Abstract: The development of 18F labeled hypoxic agents for PET imaging is mainly introduced. With the rapid development of PET imaging technique, the application of radiopharmaceuticals labeled with 18F in nuclear medicine becomes more and more widely and the hypoxic agents become the hot spots in recent radiopharmaceutical research. 18FMISO is the mostly studied of I8F labeled hypoxic agents in clinic. But because of 18FMISO having some defect, some new hypoxic agents are still need to be researched.

Key words: 18F, hypoxia imaging agents, tumor, label

中图分类号:

作者. ~(18)F标记乏氧组织显像剂的研究进展[J]. 同位素, 2004, 17 (4 ): 241-241 .

参考文献

[1] Bush RS, Jenkin RD, Allt We, et al. Definitive Evidence for Hypoxic Cells Influencing Cure in Cancer Therapy [J]. Br J Cancer Suppl, 1978, 37: 302-306. [2] H ockel M, Knoop C, Schleager K, et al. Intra-tumoral pO2 Predicts Survival in Advanced Cancer of the Uterine Cervix [J]. Radiother Oncol, 1993, 26: 45-50. [3] Brizel DM, Scully SP, Harrelson JM, et al. Tumor Oxygenation Predicts for the Likelihood of Distant Metastases in Human Soft Tissue Sarco-ma[J]. Cancer Res, 1996, 56: 941 - 943. [4] Graeber TG, Osmanian C, Jacks T, et al. Hy-poxia-mediated Selection of Cells With Diminished Apoptotic Potential in Solid Tumours [J]. Nature, 1996, 379: 88-91. [5]朱霖,刘秀杰.乏氧显像剂及其应用[J].国外医学 [放射医学核医学分册],1997,21:150-154. [6] Grunbaum Z, Freauff SJ, Krohn KA, et al. Synthesis and Characterization of Congeners of Mis-onidazole for Imaging Hypoxia[J]. J Nucl Med, 1987, 28(1): 68-75. [7] Lim JL, Berridge MS. An Efficient Radiosynthe-sis of [18F] Fluoromisonidazole [J]. Appl Radial Isot, 1993, 44(8): 1085-1091. [8] Tada M, Iwata R, Sugiyama H, et al. A Concise One-pot Synthesis of [18F ] fluoromisonidazole From (2R)-(-)-Glycidyl Tosylate [J]. Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 38(8): 771 - 773. [9] Piert M, Machulla HJ, Becker G, et al. Introducing Fluorine-18 Fluoromisonidazole Positron E-mission Tomography for the Localisation and Quantification of Pig Liver Hypoxia[J]. Eur J Nucl Med,1999, 26: 95 - 109. [10] Chang CP, Chao I, Chang CW, et al. Proceedings of the SNM 48th Annual Meeting[J]. J Nucl Med, 2001. [11] Rasey JS, Koh WJ, Evans ML, et al. Quantify-ing Regional Hypoxia in Human Tumors With Positron Emission Tomography of [18F ] fluo-romisonidazole: a Pretherapy Study of 37 Patients [J]. Int J Radial Oncol Biol Phys, 1996, 36(2): 417-428. [12] Yang DJ, Wallace S, Cherif A, et al. Development of F-18-labeled Fluoroerythronitroimida-zole as a PET Agent for Imaging Tumor Hypoxi-a[J]. Radiology, 1995, 194(3): 795-800. [13] Lehti 6 K, Oikonen V, Gr 6 nroos T, et al. Imaging of Blood Flow and Hypoxia in Head and Neck Cancer: Initial Evaluation With [(15)O] H(2)O and [(18)F]fluoroerythronitroimidazole PET[J]. J Nucl Med, 2001, 42(11): 1643-1 652. [14] Josse O, Labar D, Georges B, et al. Synthesis of [18F]-Labeled EF3[2-(2-nilroimidazole-l-y1)-N-(3,3,3-trifluoropropyl)-acetamide], a Marker for PET Detection of Hypoxia [J]. Bioorg Med Chem, 2001, 9: 665-675. [15] Dolbier WR Jr, Li AR, Koch CJ, et al. [18F]-EF5, a Marker for PET Detection of Hypoxia: Synthesis of Precursor and a New Fluorination Procedure[J]. Appl Radial Isot, 2001, 54: 73 -80. [16] Evans SM, Kachur AV, Shiue CY, et al. Non-invasive Deteclion of Tumor Hypoxia Using the 2-Nilroimidazole [18F]EF1[J]. J Nucl Med, 2000, 41(2): 327-336. [17] Rasey JS, Hofslrand PD, Chin LK, el al. Characterization of [18F]FIuoroelanidazole, a New Radiopharmaceutical for Delecting Tumor Hy-poxia[J]. J Nucl Med, 1999, 40(6): 1072-1 079. [18] Kaneta T, Takai Y, Kagaya Y, et al. Imaging of Ischemic but Viable Myocardium Using a New 18F-Labeled 2-Nitroimidazole Analog, 18F-FRP 170[J]. J Nucl Med, 2002, 43(1): 109-116. [19] Piert M, Machulla HJ, Kumar P, et al. Proceedings of the SNM 48th Annual Meeting: Sup-plement[J]. J Nucl Med, 2001. [20] Sorger D, Patt M, Kumar P, et al. [18F]Fluo-roazomycinarabinofuranoside (18FAZA) and [18 F]Fluoromisonidazole (18FMISO): a Comparative Study of Their Selective Uptake in Hypoxic Cells and PET Imaging in Experimental Rat Tumors [J]. Nucl Med Biol, 2003, 30(3): 317 -326. [21] Patt M, Sorger D, Scheunemann M, et al. Ad-duct of 2-[18F]FDG and 2-Nitroimidazole as a Putative Radiotracer for the Detection of Hypoxi-a With PET: Synthesis, in Vitro- and in Vivo-characterization[J]. Appl Radial Isot, 2002, 57 (5): 705-712. [22] Yamamoto F, Oka H, Antoku S, et al. Synthesis and Characterization of Lipophilic l-[18F]Flu-oroalkyl-2-Nitroimidazoles for Imaging Hypoxia [J]. Biol Pharm Bull, 1999, 22(6): 590-597. [23] Yamamoto F, Aoki M, Furusawa Y, et al. Synthesis and Evaluation of 4-Bromo-l-(3-[18F]flu-oropropyl)-2-nitroimidazole With a Low Energy LUMO Orbital Designed as Brain Hypoxia-Tar-geting Imaging Agent [J]. Biol Pharm Bull, 2002, 25(5): 616 - 621.

~(18)F标记乏氧组织显像剂的研究进展

The Development ~(18)F Labeled Hypoxic Imaging Agents

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	黄伟, 陈宝军, 赵思倩. ³H与¹⁴C放射性标记化合物发展现状[J]. 同位素, 2021, 34(2): 175-180.
[2]	赵海龙;李洪玉. 肿瘤诊断⁶⁴Cu标记药物临床研究进展[J]. 同位素, 2021, 34(1): 78-88.
[3]	李波;罗宁;曾俊杰;吴建荣;贾致军;王磊;孙志中;陈云明;张劲松. ¹²⁵I生产工艺研究进展与展望[J]. 同位素, 2020, 33(6): 366-373.
[4]	余凯翔;杨征敏;周兵;徐凌锋;李书琰;陈沪飞;王伟. 放射性同位素碳-14标记毒死蜱的合成与分析[J]. 同位素, 2020, 33(6): 409-416.
[5]	黄旭虎;李洪玉. 放射性核素标记耐久霉素细胞凋亡显像的研究进展[J]. 同位素, 2020, 33(6): 435-442.
[6]	邱婷;张曙盛;朱苏珍;郭寅龙. 稳定同位素D标记甜蜜素的合成[J]. 同位素, 2020, 33(5): 273-278.
[7]	孙雯;李杰;杜晓宁;徐仲杰;潘洁;尤雅芳;李美华. 邻苯二甲酸酯类标准物质在婴幼儿乳粉塑化剂检测中的应用研究[J]. 同位素, 2020, 33(5): 279-285.
[8]	周明;李玉来;杨能安;李建;陈小娟;胡硕. ［¹⁸F］-苯丙氟硼酸的制备工艺改进及初步临床应用[J]. 同位素, 2020, 33(3): 167-172.
[9]	涂亚辉;邓晓军;钟佳琪;赵超敏;罗勇;潘洁;徐仲杰. 稳定同位素标记甲基毒死蜱-D₆的合成研究[J]. 同位素, 2020, 33(3): 173-179.
[10]	黄金铭;于宁文. ¹²⁵I放射性粒子治疗癌症研究进展[J]. 同位素, 2020, 33(3): 186-198.
[11]	王淼;童永彭. 硼中子俘获治疗的进展及前景[J]. 同位素, 2020, 33(1): 14-26.
[12]	侯静华;刘占峰;杜晓宁;宋明鸣. 发酵优化制备L-赖氨酸盐酸盐-¹³C₆、¹⁵N₂[J]. 同位素, 2019, 32(6): 418-424.
[13]	刘轩;景士伟;李明非;郑彦;高亚东;年瑞雪. 基于标记中子方法的爆炸物特征γ能谱分析[J]. 同位素, 2019, 32(5): 309-314.
[14]	郭志德;张现忠;杜进. ⁶⁸Ga标记药物研究进展[J]. 同位素, 2019, 32(5): 360-374.
[15]	张晓军;付华平;李云钢;刘健;崔孟超;富丽萍;张锦明. Tau蛋白显像剂¹⁸F-THK5317的合成与初步临床应用[J]. 同位素, 2019, 32(2): 121-127.